Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | SYK | P43405 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | FYN | P06241 | 1/20 | 0.61 |
| ▸ | YES1 | P07947 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | FGR | P09769 | 1/20 | 0.61 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.61 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.61 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
| ▸ | CSK | P41240 | 1/20 | 0.61 |
| ▸ | TXK | P42681 | 1/20 | 0.61 |
| ▸ | BLK | P51451 | 1/20 | 0.61 |
| ▸ | BMX | P51813 | 1/20 | 0.61 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.61 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.61 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14292694 | 0.87 | NPC1 (0.75) | AURKASYKLCKEPHA2BLK | |
| SCHEMBL4726882 | 0.85 | AURKA (0.64) | AURKAROCK1 | |
| SCHEMBL3747896 | 0.82 | CAMKK2 (0.80) | AURKASYK | |
| SCHEMBL4903688 | 0.82 | MAPK8 (0.63) | AURKASYK | |
| SCHEMBL4903516 | 0.81 | MAPK8 (0.68) | AURKASYK | |
| SCHEMBL4712432 | 0.81 | ABL1 (0.61) | AURKASYK | |
| SCHEMBL4710600 | 0.80 | SYK (0.66) | AURKASYK | |
| SCHEMBL2945641 | 0.80 | MAPK8 (0.67) | SYKLCKFYNYES1LYN | |
| SCHEMBL4895454 | 0.80 | ABL1 (0.80) | — | |
| Hydrochloric Acid SCHEMBL27711429 | 0.79 | ABL1 (0.79) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442024-B1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-19 | — | — | EP | claimed |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | claimed |
| CN-1703405-A | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-30 | — | — | CN | claimed |
| EP-1442024-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037877-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | claimed |
| CN-100436427-C | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-26 | — | — | CN | disclosed |
| EP-1442024-B1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1442024-B1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-19 | — | — | EP | disclosed |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | disclosed |
| CN-1703405-A | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-30 | — | — | CN | disclosed |
| EP-1442024-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037877-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | GSK3B, GSK3A, PHKG1 | AURKA 492/4885SYK 1427/4885LCK 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.